Pgp (P-Glycoprotein, MDR Protein, Multi Drug Resistance Associated Protein)

Size

125ug

Hosts

Mouse

Form

Liquid. Antibody in serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide.\n

Purity

Supernatant

References

1. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies: H. Hamada & T. Tsuruo; PNAS 83, 7785 (1986) 2. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy: W.S. Dalton, et al.; J. Clin. Oncol. 7, 415 (1989) 3. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res. 51, 2628 (1991) 4. Flow cytometric analysis of P-glycoprotein in normal and leukemic cells: M.I. Tiirikainen, et al.; Ann. Hematol. 65, 124 (1992) 5. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy: T.M. Grogan, et al.; Blood 81, 490 (1993) 6. Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies: J.L. Gala, et al.; J. Clin. Pathol. 47, 619 (1994) 7. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma: M. Itsubo, et al.; Cancer 73, 298 (1994) 8. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse: F.A. Sinicrope, et al.; Cancer 74, 2908 (1994) 9. New immunohistochemical \"sandwich\" staining method for mdr1 P- glycoprotein detection with JSB-1 monoclonal antibody in formalin- fixed, paraffin-embedded human tissues: K. Toth, et al.; Am. J. Pathol. 144, 227 (1994) 10. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome: N. Baldini, et al.; N. Engl. J. Med. 333, 1380 (1995) 11. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase: V.V. Rao, et al.; J. Histochem. Cytochem. 43, 1187 (1995) 12. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy: S. Chevillard, et al.; Cancer 77, 292 (1996) 13. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42: E. Moran, et al.; Eur. J. Cancer 33, 652 (1997) 14. Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies: F.J. Lacueva, et al.; Histopathology 32, 328 (1998) 15. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival: A.G. Borg, et al.; Br. J. Haematol. 103, 1083 (1998) 16. Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors: T. Sawada, et al.; Brain Tumor Pathol. 16, 23 (1999) 17. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia: M.R. Grey, et al.; Leuk. Res. 23, 29 (1999) 18. Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma: Y.S. Kim, et al.; Clin. Nucl. Med. 24, 874 (1999) 19. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis: G.A. Meijer, et al.; J. Clin. Pathol. 52, 450 (1999) 20. Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy: R.E. Jimenez, et al.; Cancer 86, 976 (1999) 21. The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein: S. Barg, et al.; PNAS 96, 5539 (1999) 22. Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer Res. Clin. Oncol. 125, 117 (1999) 23. Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia: S. Poulain, et al.; Adv. Exp. Med. Biol. 457, 57 (1999) 24. P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma: A.P. Jillella, et al.; Cancer Invest. 18, 609 (2000) 25. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma: H.M. Coley, et al.; Eur. J. Cancer 36, 881 (2000) 26. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res. 60, 5269 (2000)